Lonza Nears Deal to Buy KKR's Capsugel
12 December 2016 - 11:50AM
Dow Jones News
Private-equity firm KKR & Co. is nearing a deal to sell
Capsugel to Switzerland's Lonza Group AG for more than $5 billion,
as an auction of the New Jersey drug-capsule maker draws to a
close.
Lonza is currently the leading bidder, according to people
familiar with the matter, though one of them cautioned that a deal
isn't guaranteed and others may still be circling. It isn't clear
whether the price includes debt or not.
Capsugel, based in Morristown, N.J., makes capsules used for the
delivery of drugs and food supplements. Its designs are used in
vitamins, over-the-counter drugs, dietary supplements and
prescription medicines. KKR bought Capsugel from pharmaceutical
giant Pfizer Inc. for $2.4 billion in 2011.
The Capsugel auction attracted a mix of health care, industrial
and Asian suitors, one of the people said.
Lonza, for its part, produces a wide range of chemical, health
care and personal-care products. Founded in 1897 as an electricity
supplier, Lonza has a market value of CHF9.4 billion ($9.2
billion), so a takeover of Capsugel would be a big bite.
Lonza has been scouring the landscape for deals. Earlier this
year, it held abortive talks to buy drug-development company
Catalent Inc. for around $4 billion, according to people familiar
with the matter.
While overall health care deal-making has dropped from last
year's brisk pace, companies that provide ancillary products and
services to the pharmaceutical and other segments have announced
several combinations lately.
Blackstone Group LP in October agreed to lead an acquisition of
healthcare-staffing provider Team Health Holdings Inc. for more
than $3 billion. Software-and-data company IMS Health Holdings Inc.
in October merged with outsourcer Quintiles Transnational Holdings
Inc. in a deal worth nearly $9 billion.
Meanwhile, private-equity firms Carlyle Group LP and Hellman
& Friedman LLC are seeking buyers for drug-research company
Pharmaceutical Product Development LLC, which could fetch about $5
billion, The Wall Street Journal reported last week.
There have been $268 billion of health care deals announced so
far in 2016, according to Dealogic, down from a total of $515
billion in all of 2015. Last year's tally would have been even
greater if Pfizer's roughly $150 billion agreement to buy drugmaker
Allergan PLC hadn't fallen apart amid resistance from the Obama
administration. The deal was to be a so-called inversion, moving
Pfizer abroad for tax purposes. Indeed, resistance in Washington is
one factor cited by deal makers for the drop in merger activity in
2016.
Write to Dana Mattioli at dana.mattioli@wsj.com
(END) Dow Jones Newswires
December 11, 2016 19:35 ET (00:35 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Team Health Holdings Team Health Holdings, Inc. (delisted) (NYSE:TMH)
Historical Stock Chart
From Nov 2024 to Dec 2024
Team Health Holdings Team Health Holdings, Inc. (delisted) (NYSE:TMH)
Historical Stock Chart
From Dec 2023 to Dec 2024